The partnership is through LLS's Therapy Acceleration ProgramŽ (TAP), through which LLS forges collaborations with biotechnology companies to help bring therapies to patients faster.
To date, 12 patients have been treated with vaccine alone in the ongoing Phase 1/2a clinical trial of PVX-410, and the trial has been expanded to include a second treatment arm adding concurrent courses of lenalidomide. If this therapy advances, it would become the only clinical stage immunotherapy for SMM patients, whose current treatment paradigm is routine monitoring for progression through watchful waiting.
As part of the partnership,
"Despite significant progress in the treatment of myeloma, it still remains a very difficult, incurable blood cancer for many patients," said Greenberger. "LLS sees great potential in this novel approach to treating smoldering multiple myeloma, which is associated with a high risk of progression to symptomatic myeloma. We look forward to partnering with
Keywords for this news article include: Biological Products, Cancer Vaccines, Clinical Trials and Studies, Hematology, Leukemia, Oncology,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Consumer Prices Edge Up, Surprising Economists
- Steris to Add 100 Jobs in Birmingham
- Clinton Rallies New England Women
- Market Jolt Offers a Reality Check for Investors
- Ebola in New York, Mali Raises Travel Jitters
- Do Voters Want Compromise?
- Beepi Eases Peer-to-peer Auto Sales
- Stocks Close Out Best Week in Nearly 2 Years
- Microsoft Earnings Drive Stocks Higher
- Timeline for New York Ebola Doctor